Neoleukin Therapeutics Inc (NLTX) Stock: What's Next?

Tuesday, June 30, 2020 4:08 PM | InvestorsObserver Analysts

Neoleukin Therapeutics Inc (NLTX) stock is up 613.30% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy. InvestorsObserver’s proprietary ranking system, gives NLTX stock a score of 85 out of a possible 100.

That rank is chiefly influenced by a short-term technical score of 99. NLTX's rank also includes a long-term technical score of 95. The fundamental score for NLTX is 60. In addition to the average rating from Wall Street analysts, NLTX stock has a mean target price of 22. This means analysts expect the stock to rise 32.37% over the next 12 months.

Overall Score - 85
NLTX has an Overall Score of 85. Find out what this means to you and get the rest of the rankings on NLTX!

What's Happening with NLTX Stock Today

Neoleukin Therapeutics Inc (NLTX) stock is up 9.78% while the S&P 500 is up 0.59% as of 3:58 PM on Tuesday, Jun 30. NLTX is up $1.48 from the previous closing price of $15.14 on volume of 508,212 shares. Over the past year the S&P 500 has gained 3.60% while NLTX is up 613.30%. NLTX lost -$2.67 per share in the over the last 12 months.

Click Here to get the full Stock Score Report on Neoleukin Therapeutics Inc (NLTX) Stock.

Share this article:

Related Companies

Upgrade to Premium and Analyze Stocks Like a Pro

40% Off All Subscriptions
InvestorsObserver Premium
InvestorsObserver Premium
InvestorsObserver Premium
Save up to 57% with annual

InvestorsObserver Premium

$ 20.75 $ 12.45 /month
$249 $149.40 billed annually

You May Also Like

Related Articles

Related Companies